UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 5, 2016
BEIGENE, LTD.
(Exact name of registrant as specified in its charter)
|
Cayman Islands |
|
001-37686 |
|
98-1209416 |
|
(State or other jurisdiction |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
of incorporation) |
|
|
|
|
c/o Mourant Ozannes Corporate Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of principal executive offices) (Zip Code)
+1 (345) 949 4123
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On June 5, 2016, BeiGene, Ltd. (the “Company”) issued a press release announcing initial clinical data from its BGB-A317 clinical trial that was presented in a poster presentation at the 2016 American Society of Clinical Oncology Annual Meeting held in Chicago, Illinois on June 5, 2016. The full text of the Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release issued on June 5, 2016 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BEIGENE, LTD. | |
|
|
|
|
|
|
|
|
|
Date: June 6, 2016 |
By: |
/s/ Howard Liang |
|
|
Name: |
Howard Liang |
|
|
Title: |
Chief Financial Officer and Chief Strategy Officer |